Q2 2025 · 13F-HR
TCG Crossover Management, LLCholdings as filed
Filed 2025-08-14 · accession 0001214659-25-012291
$875.5M
Reported value
38
Positions
2025-06-30
Period end
The Brief · TCG Crossover Management, LLC · Q2 2025
AI · grounded in 13F
TCG Crossover Management, LLC established a new position in CG Oncology Inc CGON valued at $95.4M. The fund also initiated new stakes in Tango Therapeutics Inc TNGX for $55M and Cogent Biosciences Inc COGT for $50M. Other new additions include Ocular Therapeutix Inc OCUL and Cidara Therapeutics Inc CDTX. The fund ended the period with 38 positions and total AUM of $875.5M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 156944100 | CGON | CG ONCOLOGY INC | $95.4M | 10.9% | 3,670,206 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $55.0M | 6.28% | 10,736,000 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $50.0M | 5.71% | 6,964,375 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $49.4M | 5.64% | 5,319,148 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $49.0M | 5.60% | 1,005,901 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA AMERICAN DEPOSITARY SHARES | $46.3M | 5.29% | 6,056,596 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $38.1M | 4.35% | 5,943,812 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $38.0M | 4.34% | 2,890,816 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $36.1M | 4.13% | 5,250,000 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $35.9M | 4.10% | 3,766,660 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $33.6M | 3.84% | 3,572,335 | Common | SOLE |
| 91678A107 | UPB | UPSTREAM BIO INC | $30.8M | 3.51% | 2,801,763 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $28.2M | 3.22% | 12,362,205 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $28.0M | 3.20% | 1,501,624 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $27.7M | 3.17% | 2,898,103 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $24.6M | 2.81% | 465,257 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $23.6M | 2.70% | 1,477,593 | Common | SOLE |
| 00847X104 | AGIO | Agios Pharmaceuticals, Inc. | $23.2M | 2.65% | 697,003 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $22.0M | 2.52% | 1,063,000 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $19.3M | 2.20% | 2,452,138 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $17.6M | 2.01% | 3,033,560 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $15.6M | 1.78% | 186,250 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $14.8M | 1.69% | 2,761,861 | Common | SOLE |
| 75382E208 | RAPT | RAPT Therapeutics, Inc. | $13.1M | 1.50% | 1,636,275 | Common | SOLE |
| 88427A107 | — | THIRD HARMONIC BIO INC | $10.4M | 1.19% | 1,915,424 | Common | SOLE |
| 29337E102 | ELVN | Enliven Therapeutics, Inc. | $10.0M | 1.14% | 498,000 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $7.4M | 0.85% | 650,000 | Common | SOLE |
| 640268306 | NKTR | NEKTAR THERAPEUTICS | $6.9M | 0.79% | 266,666 | Common | SOLE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $5.4M | 0.61% | 2,676,580 | Common | SOLE |
| 50015M109 | KOD | KODIAK SCIENCES INC | $4.3M | 0.49% | 1,145,538 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $4.2M | 0.48% | 735,184 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $3.9M | 0.45% | 584,955 | Common | SOLE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $3.9M | 0.44% | 1,796,482 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $2.4M | 0.28% | 483,000 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $676,657 | 0.08% | 316,195 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $639,590 | 0.07% | 64,023 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $131,928 | 0.02% | 86,795 | Common | SOLE |
| 492327101 | KROS | KEROS THERAPEUTICS INC | $0 | — | 0 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.